Home›Alpelisib

Alpelisib

Also known as: Vijoice

Route: Oral

3 interactions on record

Alpelisib has 3 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Breast Cancer Resistance Protein (Bcrp) Substrates, Cyp3a Inducers, Mao Inhibitors. Patients taking Alpelisib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Major: 3

Major (3)

Alpelisib + Breast Cancer Resistance Protein (Bcrp) Substrates— BCRP inhibitors may increase alpelisib concentration, which may increase the risk of toxicities. Avoid use or closely mo…
Alpelisib + Cyp3a Inducers— Strong CYP3A4 inducers decrease alpelisib concentration, which may reduce alpelisib efficacy. Avoid concomitant use.
Alpelisib + Mao Inhibitors— Concomitant use may increase alpelisib exposure and risk of adverse reactions. Avoid use; if unavoidable, closely monito…

Alpelisib + Breast Cancer Resistance Protein (Bcrp) Substrates⚠️Major

BCRP inhibitors may increase alpelisib concentration, which may increase the risk of toxicities. Avoid use or closely monitor for increased adverse reactions.

Alpelisib + Cyp3a Inducers⚠️Major

Strong CYP3A4 inducers decrease alpelisib concentration, which may reduce alpelisib efficacy. Avoid concomitant use.

Alpelisib + Mao Inhibitors⚠️Major

Concomitant use may increase alpelisib exposure and risk of adverse reactions. Avoid use; if unavoidable, closely monitor for increased adverse reactions.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.